What Happens When You Stop Wegovy: The Off-Ramp Evidence Base

If you are reading this with a Wegovy pen in the fridge and a finger over the cancel button, the published data is unambiguous about one thing. Most patients who stop semaglutide regain most of the weight they lost. STEP 4 showed it. The STEP 1 extension confirmed it over a longer window. A January 2026 Oxford meta-analysis of 37 studies and 9,341 adults quantified it across the GLP-1 class.

This piece is the evidence base for what happens next. We will not tell you to stop. We will not tell you to continue. We will show you what is published.

What STEP 4 actually measured

STEP 4 is the cleanest randomised trial on stopping semaglutide. The design built a withdrawal arm into a 68-week phase 3 study. All 902 enrolled adults received open-label once-weekly semaglutide 2.4 mg for the first 20 weeks; the 803 who reached the maintenance dose were re-randomised 2:1 at week 20 to continue semaglutide or switch to placebo for the remaining 48 weeks (Rubino et al., JAMA 2021; DOI 10.1001/jama.2021.3224).

From week 20 to week 68, the continued-semaglutide arm lost an additional 7.9% of body weight. The placebo arm regained 6.9%. A 14.8-percentage-point gap, p<0.001. Cumulative weight change from baseline was −17.4% on continued semaglutide versus −5.0% on placebo.

The cardiometabolic readouts moved with the weight. Waist circumference, systolic and diastolic blood pressure, fasting glucose, HbA1c, fasting insulin, and lipid markers improved during the run-in, were sustained or improved further on continued semaglutide, and deteriorated toward baseline in patients who switched to placebo (Kosiborod et al., Diabetes Obes Metab 2023). The authors' framing: continued treatment is required to maintain benefit.

What STEP 1's extension showed over a longer window

STEP 1's extension is the longer-window evidence. The original STEP 1 produced a mean weight loss of 17.3% on semaglutide 2.4 mg versus 2.0% on placebo over 68 weeks. Treatment and lifestyle intervention were both stopped at week 68, and a 327-patient subset was followed for a further 52 weeks off treatment, through week 120 (Wilding et al., Diabetes Obes Metab 2022; PMC).

By week 120 — one year after the last dose — the semaglutide group had regained a mean of 11.6 percentage points against a peak loss of 17.3%. Roughly two-thirds of the lost weight back within a year. Net weight loss from original baseline was 5.6%, and cardiometabolic improvements reverted toward baseline in parallel. The half-full reading: 48.2% still had at least 5% weight loss from baseline a year after stopping. The half-empty: two-thirds came back without the drug. Both are correct.

The Oxford meta-analysis: the class-wide answer

The most useful single publication on this question dropped on January 8, 2026. Oxford's Nuffield Department of Primary Care Health Sciences published a systematic review and meta-analysis in The BMJ pooling 37 studies and 9,341 adults (Oxford press release; BMJ Group summary).

The headline finding: after stopping anti-obesity pharmacotherapy, body weight increased by an average of 0.4 kg per month across the pooled cohort. For newer GLP-1s — semaglutide and tirzepatide — the rate accelerated to approximately 0.8 kg per month, projecting a return to pre-treatment baseline within roughly 1.5 to 2 years. Medication discontinuation drove regain roughly 0.3 kg/month faster than discontinuation of a behavioural weight-loss programme. Cardiometabolic markers tracked the weight back toward baseline.

This is the most defensible class-wide regain figure in the published literature as of mid-2026. The "64%-within-12-months" number that circulates on patient forums is harder to source to a specific paper; the published evidence supports 0.8 kg/month for newer GLP-1s and roughly two-thirds of lost weight regained within a year for semaglutide. Use the sourced numbers.

What the science says about why it comes back

Semaglutide works while it is in your bloodstream. The molecule resists DPP-4 enzymatic breakdown and binds albumin via a fatty-acid side chain, extending its half-life to about seven days (Wegovy FDA label). After the last dose, blood levels fall through five half-lives over roughly 35 days, below biologically active thresholds.

The mechanisms reverse on the same clock. Gastric emptying — slowed roughly twofold on therapeutic-dose semaglutide — speeds back up. The central satiety effect at hypothalamic and brainstem GLP-1 receptors fades; the food-noise that quieted on treatment returns. Patients commonly describe the return within the two-to-six-week window after the last dose. The regain is not a behavioural failure. It is an appetite-signalling system reverting to its untreated baseline.

What stays after you stop

A subset of benefits persists. Cardiometabolic markers — blood pressure, fasting glucose, HbA1c, triglycerides — partly persist for months before trending back toward baseline. STEP 1's extension reports cardiometabolic readings at week 120 that were intermediate between week-68 peak benefit and original baseline (Wilding et al. 2022). About half of extension participants still met the 5%-weight-loss threshold at week 120 — meaningful for prediabetes reversal, sleep apnea improvement, or surgical-risk reduction tied to weight at the point of intervention.

The tirzepatide evidence tells the same story with sharper edges. SURMOUNT-4 randomised 670 patients to continue or stop tirzepatide after 36 weeks; the placebo arm regained an average of 14% of body weight over the next year, with 82% regaining more than 25% of lost weight (SURMOUNT-4, ACC 2025).

The case for staying — and the case for stopping

The case for continuing indefinitely is the chronic-disease framing. The ADA's 2026 Standards of Care treats obesity as a chronic disease requiring long-term pharmacotherapy. AACE's 2025 guidance and the WHO's December 2025 GLP-1 guideline converge on the same position: the medication works while taken, the rebound is the default when stopped, and intermittent treatment is not how other chronic diseases are managed.

The case for stopping has its own clinical territory. The FDA Wegovy label advises discontinuation at least two months before conception. Patients facing surgery may need to discontinue for anaesthesia-related reasons (delayed gastric emptying is a documented intraoperative concern). Intolerable side effects after a full titration trial are a clear case. So is cost without insurance coverage — and if stopping is being forced on you because your compounded prescription was discontinued, the brand and 503A paths are worth weighing before you treat stopping as the only option. When the driver is purely cost, see how to come off safely when cost is the reason. Some patients reach a weight-loss goal and prefer a structured trial off the drug with the understanding that re-starting is an option.

What the evidence does not support is the framing that you "should" come off after a year because the drug "isn't meant long-term." The current professional consensus is the opposite.

What a structured off-ramp looks like in clinical practice

The published evidence on structured discontinuation is sparser than it should be. What follows describes what obesity-medicine programs commonly do, drawn from guideline language and clinical commentary rather than from a definitive trial. Descriptive, not prescriptive.

Most structured off-ramp protocols share four elements. A stepped dose-down through the FDA-approved Wegovy dose ladder (2.4 → 1.7 → 1.0 → 0.5 → 0.25 mg) over weeks to months. An explicit nutritional handoff, often with dietitian contact rising across the taper, because the food-environment skills the patient now needs have been less practised under pharmacological appetite suppression. A behavioural-support layer — structured weigh-ins, group-based maintenance, or app-mediated check-ins. And a pre-agreed re-start threshold, typically 5% or 10% regain from the post-treatment nadir.

The under-discussed alternative is the maintenance-dose option. Some clinicians transition patients to a sub-therapeutic weekly dose (Wegovy 1.0 mg or 1.7 mg) to preserve weight loss at lower cost and lower side-effect burden. The evidence base is thinner than for full continuation but thicker than for structured stopping.

The data gap

Long-term (>2-year) randomised follow-up after planned semaglutide discontinuation with structured maintenance support does not exist as a published trial as of May 2026. STEP 1's extension follows patients for one year off treatment; the Oxford meta-analysis has an average post-discontinuation follow-up of 32 weeks. The maintenance-dose option is an active research question, not a settled answer. Whether structured behavioural support attenuates regain has not been quantified head-to-head against stopping without support. If you are deciding, you are deciding with the evidence we have. It is not enough to make the choice obvious in either direction.

What to discuss with your prescriber

Six questions, ranked by what the data suggests matters most:

1. Given my starting BMI, percentage of body weight lost, and duration of therapy, what is the realistic regain projection if I stop now?
2. What dose taper schedule do you recommend, and what is your evidence basis?
3. What nutritional and behavioural support is built into the off-ramp?
4. Is a maintenance-dose option (a sub-therapeutic weekly dose continued indefinitely) appropriate for me?
5. If I regain a defined amount of weight, what is the protocol for restarting, and how is that handled by my insurance?
6. Are there current discontinuation trials I could enrol in?

This page is awaiting medical-reviewer signoff and does not yet constitute medical advice. See our disclaimer and the methodology page for how we source and verify clinical claims.

How we keep this article current

We refresh this page on any new randomised trial readout, guideline update from ADA, AACE, WHO, or the Obesity Society, or FDA label change. Three areas tend to drift faster than the rest:

• The structured-discontinuation evidence base. This is the most active research area in obesity medicine; additional randomised readouts on planned discontinuation with structured maintenance support are expected across 2026 and 2027.
• The maintenance-dose question. A parallel open question with active trials.
• Obesity-medicine guideline framing. It is shifting fast toward the chronic-disease default, which changes the default answer to "should I stop?"

Errors and missing sources: [email protected].